Menu Back to Pharmacovigilance-Strategies-Workshop


Engage in the sharing of good practices between industry representatives and seek advice from regulators in this unique workshop

Linking Industry and Regulators in stimulating discussions is what makes the DIA community special. Join the DIA Pharmacovigilance Strategies Workshopto benefit from the outstanding knowledge of our excellent speakers, sharing their insights and best practices.

Finally, back in a face-to-face format, you get the opportunity to broaden your network and meet key-stakeholders from regulation and industry in person.

The workshop format is tailored to stimulate dialogue and generate solutions through interactive sessions and workshops. Enjoy an informal setting with in-depth discussions in smaller groups.

Expect cutting-edge topics, selected by the committee and the DIA team.

More detailed information about this event will be shared soon. Stay tuned!

Featured topics

  • Pharmacovigilance Guidelines and Regulations Updates (EU, non-EU, Global)
  • Globalisation of PSMF : Practical Implementation
  • Lessons Learnt from the Experiences with COVID-19 Vaccines
  • Workshop: Future Changes and Challenges in PV
  • Data Science and Standards : Impact on Pharmacovigilance
  • Social Media and Patient Support Programmes
  • Medical devices, wearables, combination products
  • Cooperation between marketing authorisation holders

Who should attend?

Established professionals who are seeking to increase their network of like-minded colleagues; share their thoughts and practices with others; learn the most current regulatory views and gain practical knowledge in key areas in pharmacovigilance, including:

  • Signal management
  • Data Privacy
  • Risk Management Planning
  • PSMF maintenance
  • Clinical Trials

Professionals involved in:

  • Drug Safety/Pharmacovigilance
  • Risk Management, including Risk Evaluation and Mitigation Strategies (REMS)
  • Benefit-risk assessment and communication
  • Medical Product Safety Assessment
  • Regulatory Intelligence
  • Clinical Trials
  • Pharmaceuticals, biologics, combination products, devices
  • Clinical Research and Clinical Research Organizations
  • Pharmacoepidemiology
  • Academic Research Centers
  • Regulatory Agencies

Learning objectives

  • Connect with experts and colleagues in pharmacovigilance
  • Learn in an interactive format through exchange of ideas and in-depth discussion
  • Understand the regulators’ expectations around pharmacovigilance and how to manage these
  • Find the answers to the day-to-day challenges you face
  • Exchange experiences, and contribute to solutions

Program Committee

    Ipsen, France
  • Wendy  Huisman, PharmD
    Wendy Huisman, PharmD Director
    Vigifit, Netherlands
  • Shahin  Kauser
    Shahin Kauser Leading Senior Scientific Assessor
    MHRA, United Kingdom
  • Maarten  Lagendijk, MSc
    Maarten Lagendijk, MSc Deputy EU QPPV
    MSD B.V., Netherlands
  • Bianca  Mulder, PharmD, MPharm, MSc
    Bianca Mulder, PharmD, MPharm, MSc Pharmacovigilance Assessor
    Medicines Evaluation Board, Netherlands
  • Willemijn  van der Spuij, MSc
    Willemijn van der Spuij, MSc Executive Director, WorldWide Patient Safety International, Europe
    Bristol-Myers Squibb, Switzerland
  • James  Whitehead, MSc
    James Whitehead, MSc Patient Safety Medical Device Lead
    Astrazeneca, United Kingdom
  • Claudia   Ferreira
    Claudia Ferreira Scientific Programs Team
    DIA, Switzerland
Load More

Contact us

Registration Questions?

Send Email
+41 61 225 51 51

Digital Learning Catalog

DIA Learning: eLearning Soultions